ImmunoPrecise Antibodies Ltd. Files 6-K with Press Release
Ticker: HYFT · Form: 6-K · Filed: Jan 22, 2025 · CIK: 1715925
Sentiment: neutral
Topics: filing, press-release, regulatory-update
TL;DR
IPA files 6-K with Jan 22 press release, check Exhibit 99.1 for details.
AI Summary
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on January 22, 2025, to report a press release dated January 22, 2025. The filing indicates the company is a foreign private issuer and will file annual reports under Form 20-F. The press release itself is included as Exhibit 99.1.
Why It Matters
This filing provides an update from ImmunoPrecise Antibodies Ltd., potentially containing material information for investors regarding their business operations or strategic developments.
Risk Assessment
Risk Level: low — This filing is a routine submission of a press release and does not contain new financial data or significant corporate actions that would inherently increase risk.
Key Players & Entities
- ImmunoPrecise Antibodies Ltd. (company) — Filer of the 6-K report
- January 22, 2025 (date) — Date of the press release and filing
- Jennifer Bath (person) — Signatory for ImmunoPrecise Antibodies Ltd.
- Form 20-F (document) — Annual report form to be filed by the registrant
- Exhibit 99.1 (document) — Press Release dated January 22, 2025
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report a press release dated January 22, 2025, as required for foreign private issuers.
What is the filing date of this report?
The filing date of this report is January 22, 2025.
Which exhibit contains the press release?
Exhibit 99.1 contains the press release dated January 22, 2025.
What type of annual report will ImmunoPrecise Antibodies Ltd. file?
ImmunoPrecise Antibodies Ltd. will file annual reports under Form 20-F.
Who signed the report on behalf of ImmunoPrecise Antibodies Ltd.?
Jennifer Bath signed the report on behalf of ImmunoPrecise Antibodies Ltd.
Filing Stats: 144 words · 1 min read · ~1 pages · Grade level 11.4 · Accepted 2025-01-22 10:30:06
Filing Documents
- press_release_jan_22_202.htm (6-K) — 23KB
- ipa-ex99_1.htm (EX-99.1) — 25KB
- 0000950170-25-007566.txt ( ) — 50KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMUNOPRECISE ANTIBODIES LTD. Date: January 22, 2025 By: /s/ Jennifer Bath Name: Jennifer Bath Title: President and Chief Executive Officer